Time Frame |
Treatment-emergent adverse events (AEs) were collected and defined as those AEs that occurred after the first dose of study medication and up to 30 days after the last dose of study medication. AEs were collected for approximately 4 years.
|
Adverse Event Reporting Description |
Safety analysis set included all participants who received at least one dose of study drug/s and had at least one postbaseline safety evaluation. AE severity was assessed using Common Terminology for Adverse Events (CTCAE). Serious AEs were followed until the event resolved or the event or sequelae stabilized.
|
|
Arm/Group Title
|
Phase 1b (Cohort 1): 12 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 2): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 3): 24 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 4): 24 mg Lenvatinib Plus 10 mg Everolimus
|
Phase 2 (Arm A): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 2 (Arm B): 24 mg Lenvatinib
|
Phase 2 (Arm C): 10 mg Everolimus
|
Arm/Group Description |
Oral lenvatinib (12 mg) and everoli...
|
Oral lenvatinib (18 mg) and everoli...
|
Oral lenvatinib (24 mg) and everoli...
|
The DLT was achieved and no partici...
|
Oral lenvatinib (18mg) and everolim...
|
Oral lenvatinib (24 mg) was taken o...
|
Oral everolimus (10 mg) was taken o...
|
Arm/Group Description |
Oral lenvatinib (12 mg) and everolimus (5 mg) were taken once daily in continuous 28-day cycles. Dose Escalation Cohort-Cycle 1: both study drugs were taken at the same time of day in a fasting state with water. Cycles 2, 3, etc. and Expansion Cohort: both study drugs were taken at the same time of day with water, either after a meal or in a fasting state. Dose escalation began with 3 participants in Cohort 1. If no dose-limiting toxicity (DLT) occurred, then enrollment proceeded to Cohort 2. If 1 participant had a DLT, 3 more participants were enrolled in Cohort 1. If 1 or none of the 6 participants had a DLT, then enrollment proceeded to Cohort 2.
If 2 or more participants had a DLT during Cycle 1, the dose escalation committee (DEC) decided if they were lenvatinib-related and if enrollment could proceed, lenvatinib was reduced to 6 mg daily (everolimus dose was not reduced). If it could not be determined that the DLTs were lenvatinib-related, enrollment stopped.
|
Oral lenvatinib (18 mg) and everolimus (5 mg) were taken once daily in continuous 28-day cycles. Dose Escalation Cohort-Cycle 1: both study drugs were taken at the same time of day in the fasting state with water. Cycles 2, 3, etc. and Expansion Cohort: both study drugs were taken at the same time of day with water, either after a meal or in a fasting state. Dose escalation began with 3 participants in Cohort 1. If no DLT occurred, then enrollment would proceed to Cohort 3. If 1 participant had a DLT, 3 more participants were enrolled in Cohort 2. If 1 or none of the 6 participants exhibited a DLT, enrollment proceeded to Cohort 3.
If 2 or more participants had a DLT during Cycle 1, dose escalation ceased and additional participants were enrolled to the next lower dose to achieve a total of 6 participants in that cohort.
|
Oral lenvatinib (24 mg) and everolimus (5 mg) were taken once daily in continuous 28-day cycles. Dose Escalation Cohort-Cycle 1: both study drugs were taken at the same time of day in the fasting state with water. Cycles 2, 3, etc. and Expansion Cohort: both study drugs were taken at the same time of day with water, either after a meal or in a fasting state. Dose escalation began with 3 participants in Cohort 1. If no DLT occurred, then enrollment proceeded to Cohort 4. If 1 participant had a DLT, 3 more participants were enrolled Cohort 3. If 1 or none of the 6 participants exhibited a DLT, then enrollment proceeded to Cohort 4.
If 2 or more participants had a DLT during Cycle 1, dose escalation ceased and additional participants were enrolled to the next lower dose to achieve a total of 6 participants in that cohort.
|
The DLT was achieved and no participants were enrolled into this cohort.
|
Oral lenvatinib (18mg) and everolimus (5 mg) were taken once daily in the morning (consistently with or without food) with water, in continuous 28-day (4-week) cycles. Treatment cycles began with the first dose of study drug in Cycle 1 and continued in 28-day (4-week) consecutive cycles until completion of the off-treatment assessments (within 30 days after the last study treatment administration). Study drugs were administered at the clinic for the first dose and on the pharmacokinetic (PK) sampling days.
|
Oral lenvatinib (24 mg) was taken once daily in the morning (consistently with or without food) with water, in continuous 28-day (4-week) cycles.
|
Oral everolimus (10 mg) was taken once daily in the morning (consistently either with or without food) with water, in continuous 28-day (4 week) cycles.
|
|
|
Phase 1b (Cohort 1): 12 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 2): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 3): 24 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 4): 24 mg Lenvatinib Plus 10 mg Everolimus
|
Phase 2 (Arm A): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 2 (Arm B): 24 mg Lenvatinib
|
Phase 2 (Arm C): 10 mg Everolimus
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
6/7 (85.71%) |
9/11 (81.82%) |
0/2 (0.00%) |
0/0 |
43/51 (84.31%) |
40/52 (76.92%) |
45/50 (90.00%) |
|
|
Phase 1b (Cohort 1): 12 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 2): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 3): 24 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 4): 24 mg Lenvatinib Plus 10 mg Everolimus
|
Phase 2 (Arm A): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 2 (Arm B): 24 mg Lenvatinib
|
Phase 2 (Arm C): 10 mg Everolimus
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
6/7 (85.71%) |
8/11 (72.73%) |
0/2 (0.00%) |
0/0 |
30/51 (58.82%) |
28/52 (53.85%) |
21/50 (42.00%) |
Blood and lymphatic system disorders |
|
|
|
|
|
|
|
Anaemia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
1/52 (1.92%) |
4/50 (8.00%) |
Sideroblastic Anaemia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Thrombocytopenia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
0/52 (0.00%) |
0/50 (0.00%) |
Cardiac disorders |
|
|
|
|
|
|
|
Cardiomyopathy |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Myocardial Infarction |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
Acute Myocardial Infarction |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
3/52 (5.77%) |
1/50 (2.00%) |
Cardiac Failure |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Cardiac Failure Congestive |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Tachycardia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Ear and labyrinth disorders |
|
|
|
|
|
|
|
Vertigo Positional |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Endocrine disorders |
|
|
|
|
|
|
|
Inappropriate Antidiuretic Hormone Secretion |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Gastrointestinal disorders |
|
|
|
|
|
|
|
Abdominal Pain |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
0/50 (0.00%) |
Gastritis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Vomiting |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
0/50 (0.00%) |
Diarrhoea |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
0/52 (0.00%) |
0/50 (0.00%) |
Dysphagia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Gastric Haemorrhage |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Ileus |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Haemorrhoids |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
General disorders |
|
|
|
|
|
|
|
Fatigue |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
General Physical Health Deterioration |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
0/50 (0.00%) |
Non-Cardiac Chest Pain |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Asthenia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
1/50 (2.00%) |
Chest Discomfort |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
1/50 (2.00%) |
Pyrexia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
1/50 (2.00%) |
Hepatobiliary disorders |
|
|
|
|
|
|
|
Cholangitis |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Cholecystitis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
0/50 (0.00%) |
Cholecystitis Acute |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Immune system disorders |
|
|
|
|
|
|
|
Drug Hypersensitivity |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Infections and infestations |
|
|
|
|
|
|
|
Cellulitis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Lung Infection |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Appendicitis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Appendicitis Perforated |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Bronchopneumonia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Diabetic Foot Infection |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Escherichia Sepsis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
1/50 (2.00%) |
Infection |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Infectious Pleural Effusion |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Lower Respiratory Tract Infection |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
2/50 (4.00%) |
Osteomyelitis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
1/50 (2.00%) |
Parotitis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Pneumonia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
1/50 (2.00%) |
Rectal Abscess |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Sepsis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
1/50 (2.00%) |
Upper Respiratory Tract Infection |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Injury, poisoning and procedural complications |
|
|
|
|
|
|
|
Joint Dislocation |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Spinal Compression Fracture |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Toxicity to Various Agents |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Investigations |
|
|
|
|
|
|
|
Ejection Fraction Decreased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
White Blood Cell Count Decreased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Blood Bilirubin Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Blood Creatinine Phosphokinase Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Body Temperature Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Electrocardiogram Repolarisation Abnormality |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Fibrin D Dimer Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Transaminases Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Lipase Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Metabolism and nutrition disorders |
|
|
|
|
|
|
|
Dehydration |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hypercholesterolaemia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Hyponatraemia |
2/7 (28.57%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Decreased Appetite |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Failure to Thrive |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Glucose Tolerance Impaired |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Hyperkalaemia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hypomagnesaemia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Malnutrition |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Hypokalaemia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
Musculoskeletal and connective tissue disorders |
|
|
|
|
|
|
|
Arthralgia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Back Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
Flank Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
0/50 (0.00%) |
Haemarthrosis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Musculoskeletal Chest Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
0/50 (0.00%) |
Psoriatic Arthropathy |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Pathological Fracture |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Spinal Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
|
|
|
|
|
Metastatic Pain |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Malignant Pleural Effusion |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Nervous system disorders |
|
|
|
|
|
|
|
Cerebral Haemorrhage |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Convulsion |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
1/50 (2.00%) |
Haemorrhage Intracranial |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Headache |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
3/52 (5.77%) |
1/50 (2.00%) |
Ischaemic Stroke |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Paresis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Posterior Reversible Encephalopathy Syndrome |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Somnolence |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Spinal Cord Compression |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Trigeminal Neuralgia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Carotid Artery Occlusion |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Psychiatric disorders |
|
|
|
|
|
|
|
Anxiety |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Confusional State |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
0/50 (0.00%) |
Renal and urinary disorders |
|
|
|
|
|
|
|
Proteinuria |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Renal Failure Acute |
1/7 (14.29%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
4/52 (7.69%) |
0/50 (0.00%) |
Haematuria |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Renal Impairment |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
0/50 (0.00%) |
Reproductive system and breast disorders |
|
|
|
|
|
|
|
Benign Prostatic Hyperplasia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
|
|
|
Dyspnoea |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
2/50 (4.00%) |
Pleural Effusion |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Acute Respiratory Failure |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
1/50 (2.00%) |
Haemoptysis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Pneumonitis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
3/50 (6.00%) |
Pulmonary Embolism |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
1/50 (2.00%) |
Vascular disorders |
|
|
|
|
|
|
|
Deep Vein Thrombosis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Hot Flush |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Subclavian Vein Thrombosis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Venous Thrombosis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Term from vocabulary, MedDRA 19.1
Indicates events were collected by non-systematic assessment
Indicates events were collected by systematic assessment
|
|
Frequency Threshold for Reporting Other Adverse Events
|
5%
|
|
Phase 1b (Cohort 1): 12 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 2): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 3): 24 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 1b (Cohort 4): 24 mg Lenvatinib Plus 10 mg Everolimus
|
Phase 2 (Arm A): 18 mg Lenvatinib Plus 5 mg Everolimus
|
Phase 2 (Arm B): 24 mg Lenvatinib
|
Phase 2 (Arm C): 10 mg Everolimus
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
7/7 (100.00%) |
11/11 (100.00%) |
2/2 (100.00%) |
0/0 |
51/51 (100.00%) |
51/52 (98.08%) |
50/50 (100.00%) |
Blood and lymphatic system disorders |
|
|
|
|
|
|
|
Anaemia |
2/7 (28.57%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
7/51 (13.73%) |
3/52 (5.77%) |
11/50 (22.00%) |
Haemorrhagic Disorder |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Lymphadenopathy |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Neutropenia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Thrombocytopenia |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
5/51 (9.80%) |
1/52 (1.92%) |
4/50 (8.00%) |
Cardiac disorders |
|
|
|
|
|
|
|
Angina Pectoris |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Aortic Valve Incompetence |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Coronary Artery Disease |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Coronary Artery Occlusion |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Mitral Valve Incompetence |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Palpitations |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
2/50 (4.00%) |
Tachycardia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
0/50 (0.00%) |
Ventricular Hypokinesia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Left ventricular dysfunction |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Ear and labyrinth disorders |
|
|
|
|
|
|
|
Ear Pain |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Vertigo |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
3/52 (5.77%) |
0/50 (0.00%) |
Endocrine disorders |
|
|
|
|
|
|
|
Hypothyroidism |
1/7 (14.29%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
12/51 (23.53%) |
19/52 (36.54%) |
1/50 (2.00%) |
Inappropriate Antidiuretic Hormone Secretion |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Eye disorders |
|
|
|
|
|
|
|
Diplopia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Eye Swelling |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Ocular Hyperaemia |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Vision Blurred |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Gastrointestinal disorders |
|
|
|
|
|
|
|
Abdominal Pain |
1/7 (14.29%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
12/51 (23.53%) |
11/52 (21.15%) |
1/50 (2.00%) |
Abdominal Pain Upper |
2/7 (28.57%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
8/51 (15.69%) |
7/52 (13.46%) |
3/50 (6.00%) |
Anal Pruritus |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Anorectal Discomfort |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Aphthous Stomatitis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
0/50 (0.00%) |
Constipation |
3/7 (42.86%) |
4/11 (36.36%) |
1/2 (50.00%) |
0/0 |
6/51 (11.76%) |
19/52 (36.54%) |
9/50 (18.00%) |
Diarrhoea |
3/7 (42.86%) |
7/11 (63.64%) |
1/2 (50.00%) |
0/0 |
43/51 (84.31%) |
37/52 (71.15%) |
17/50 (34.00%) |
Dry Mouth |
1/7 (14.29%) |
0/11 (0.00%) |
1/2 (50.00%) |
0/0 |
2/51 (3.92%) |
6/52 (11.54%) |
3/50 (6.00%) |
Dyspepsia |
0/7 (0.00%) |
4/11 (36.36%) |
0/2 (0.00%) |
0/0 |
6/51 (11.76%) |
6/52 (11.54%) |
6/50 (12.00%) |
Flatulence |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
3/52 (5.77%) |
0/50 (0.00%) |
Gastric Haemorrhage |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Gastritis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
0/52 (0.00%) |
0/50 (0.00%) |
Gastrooesophageal Reflux Disease |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
2/52 (3.85%) |
0/50 (0.00%) |
Gingival Bleeding |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
0/50 (0.00%) |
Glossitis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Glossodynia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
0/50 (0.00%) |
Haemorrhoidal Haemorrhage |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Haemorrhoids |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
0/50 (0.00%) |
Lip Discolouration |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Nausea |
6/7 (85.71%) |
6/11 (54.55%) |
1/2 (50.00%) |
0/0 |
22/51 (43.14%) |
32/52 (61.54%) |
8/50 (16.00%) |
Oral Mucosal Blistering |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Oral Pain |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
6/51 (11.76%) |
5/52 (9.62%) |
1/50 (2.00%) |
Paraesthesia Oral |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Stomatitis |
4/7 (57.14%) |
7/11 (63.64%) |
2/2 (100.00%) |
0/0 |
15/51 (29.41%) |
13/52 (25.00%) |
21/50 (42.00%) |
Vomiting |
5/7 (71.43%) |
5/11 (45.45%) |
1/2 (50.00%) |
0/0 |
24/51 (47.06%) |
20/52 (38.46%) |
6/50 (12.00%) |
Abdominal Pain Lower |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
0/50 (0.00%) |
Anal Fissure |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
0/50 (0.00%) |
Cheilitis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
1/50 (2.00%) |
Toothache |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
5/51 (9.80%) |
3/52 (5.77%) |
1/50 (2.00%) |
Mouth Ulceration |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
5/51 (9.80%) |
0/52 (0.00%) |
5/50 (10.00%) |
Abdominal Discomfort |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
0/50 (0.00%) |
Abdominal Distension |
0/7 (0.00%) |
1/11 (9.09%) |
1/2 (50.00%) |
0/0 |
4/51 (7.84%) |
2/52 (3.85%) |
0/50 (0.00%) |
General disorders |
|
|
|
|
|
|
|
Asthenia |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
13/51 (25.49%) |
8/52 (15.38%) |
3/50 (6.00%) |
Chills |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
3/52 (5.77%) |
1/50 (2.00%) |
Fatigue |
4/7 (57.14%) |
11/11 (100.00%) |
2/2 (100.00%) |
0/0 |
26/51 (50.98%) |
21/52 (40.38%) |
16/50 (32.00%) |
Gait Disturbance |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
1/50 (2.00%) |
Localised Oedema |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Non-Cardiac Chest Pain |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
1/50 (2.00%) |
Oedema Peripheral |
1/7 (14.29%) |
6/11 (54.55%) |
0/2 (0.00%) |
0/0 |
15/51 (29.41%) |
9/52 (17.31%) |
9/50 (18.00%) |
Pyrexia |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
9/51 (17.65%) |
5/52 (9.62%) |
5/50 (10.00%) |
Influenza Like Illness |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
2/52 (3.85%) |
0/50 (0.00%) |
Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
2/52 (3.85%) |
1/50 (2.00%) |
Malaise |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
3/52 (5.77%) |
1/50 (2.00%) |
Peripheral Swelling |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
5/51 (9.80%) |
1/52 (1.92%) |
2/50 (4.00%) |
Hepatobiliary disorders |
|
|
|
|
|
|
|
Dilatation Intrahepatic Duct Acquired |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Infections and infestations |
|
|
|
|
|
|
|
Bronchitis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
4/52 (7.69%) |
1/50 (2.00%) |
Cellulitis |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Infectious Pleural Effusion |
0/7 (0.00%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Influenza |
2/7 (28.57%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
Lymph Gland Infection |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Nasopharyngitis |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
7/51 (13.73%) |
4/52 (7.69%) |
7/50 (14.00%) |
Oral Herpes |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
3/50 (6.00%) |
Osteomyelitis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Paronychia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Pneumonia |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
1/50 (2.00%) |
Sinusitis |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
0/50 (0.00%) |
Skin Infection |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Upper Respiratory Tract Infection |
2/7 (28.57%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
7/52 (13.46%) |
7/50 (14.00%) |
Urinary Tract Infection |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
4/52 (7.69%) |
3/50 (6.00%) |
Lower Respiratory Tract Infection |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
4/52 (7.69%) |
4/50 (8.00%) |
Respiratory Tract Infection |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
4/52 (7.69%) |
1/50 (2.00%) |
Gingivitis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
0/52 (0.00%) |
0/50 (0.00%) |
Injury, poisoning and procedural complications |
|
|
|
|
|
|
|
Arthropod Bite |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Contusion |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
Fall |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
1/50 (2.00%) |
Periorbital Contusion |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Toxicity to Various Agents |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Investigations |
|
|
|
|
|
|
|
Alanine Aminotransferase Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
5/51 (9.80%) |
3/52 (5.77%) |
3/50 (6.00%) |
Amylase Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
0/50 (0.00%) |
Aspartate Aminotransferase Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
2/52 (3.85%) |
3/50 (6.00%) |
Blood Alkaline Phosphatase Increased |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
2/50 (4.00%) |
Blood Bilirubin Increased |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
Blood Cholesterol Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
2/52 (3.85%) |
3/50 (6.00%) |
Blood Creatine Phosphokinase Increased |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
0/52 (0.00%) |
1/50 (2.00%) |
Blood Glucose Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
1/50 (2.00%) |
Blood Phosphorus Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
0/50 (0.00%) |
Blood Potassium Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Blood Triglycerides Increased |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
1/50 (2.00%) |
Cardiac Murmur |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Computerised Tomogram Thorax Abnormal |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Ejection Fraction Decreased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
4/52 (7.69%) |
0/50 (0.00%) |
Electrocardiogram QT Prolonged |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
0/50 (0.00%) |
Haemoglobin Decreased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
5/50 (10.00%) |
Lipase Increased |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
5/52 (9.62%) |
3/50 (6.00%) |
Liver Function Test Abnormal |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Murphy's Sign Positive |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Platelet Count Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Protein Urine Present |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Transaminases Increased |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Weight Decreased |
2/7 (28.57%) |
5/11 (45.45%) |
0/2 (0.00%) |
0/0 |
16/51 (31.37%) |
26/52 (50.00%) |
4/50 (8.00%) |
White Blood Cell Count Decreased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
White Blood Cell Count Increased |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Blood Thyroid Stimulating Hormone Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
7/51 (13.73%) |
2/52 (3.85%) |
1/50 (2.00%) |
Blood Creatinine Increased |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
2/52 (3.85%) |
4/50 (8.00%) |
Metabolism and nutrition disorders |
|
|
|
|
|
|
|
Decreased Appetite |
3/7 (42.86%) |
6/11 (54.55%) |
1/2 (50.00%) |
0/0 |
27/51 (52.94%) |
30/52 (57.69%) |
10/50 (20.00%) |
Dehydration |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
1/50 (2.00%) |
Failure to Thrive |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hypercalcaemia |
2/7 (28.57%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hypercholesterolaemia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
18/51 (35.29%) |
6/52 (11.54%) |
8/50 (16.00%) |
Hyperglycaemia |
2/7 (28.57%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
8/51 (15.69%) |
3/52 (5.77%) |
12/50 (24.00%) |
Hyperkalaemia |
1/7 (14.29%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
3/52 (5.77%) |
1/50 (2.00%) |
Hyperlipidaemia |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Hypernatraemia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hypertriglyceridaemia |
1/7 (14.29%) |
7/11 (63.64%) |
0/2 (0.00%) |
0/0 |
18/51 (35.29%) |
7/52 (13.46%) |
12/50 (24.00%) |
Hypophagia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hypophosphataemia |
3/7 (42.86%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
1/50 (2.00%) |
Hypovolaemia |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Malnutrition |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Metabolic Acidosis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hypomagnesaemia |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
4/52 (7.69%) |
0/50 (0.00%) |
Hypocalcaemia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
3/52 (5.77%) |
2/50 (4.00%) |
Hypokalaemia |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
7/51 (13.73%) |
0/52 (0.00%) |
1/50 (2.00%) |
Hyponatraemia |
1/7 (14.29%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Musculoskeletal and connective tissue disorders |
|
|
|
|
|
|
|
Arthralgia |
4/7 (57.14%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
14/51 (27.45%) |
13/52 (25.00%) |
7/50 (14.00%) |
Back Pain |
3/7 (42.86%) |
4/11 (36.36%) |
0/2 (0.00%) |
0/0 |
11/51 (21.57%) |
11/52 (21.15%) |
7/50 (14.00%) |
Flank Pain |
0/7 (0.00%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
2/52 (3.85%) |
2/50 (4.00%) |
Intervertebral Disc Protrusion |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Muscle Spasms |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
2/50 (4.00%) |
Muscular Weakness |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
3/52 (5.77%) |
0/50 (0.00%) |
Musculoskeletal Chest Pain |
1/7 (14.29%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
8/51 (15.69%) |
7/52 (13.46%) |
2/50 (4.00%) |
Musculoskeletal Pain |
3/7 (42.86%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
8/52 (15.38%) |
1/50 (2.00%) |
Myalgia |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
7/52 (13.46%) |
1/50 (2.00%) |
Neck Pain |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
1/50 (2.00%) |
Pain in Extremity |
2/7 (28.57%) |
4/11 (36.36%) |
0/2 (0.00%) |
0/0 |
6/51 (11.76%) |
6/52 (11.54%) |
3/50 (6.00%) |
Spinal Osteoarthritis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Bone Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
4/52 (7.69%) |
2/50 (4.00%) |
Groin Pain |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
1/52 (1.92%) |
0/50 (0.00%) |
Pain In Jaw |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
0/50 (0.00%) |
Nervous system disorders |
|
|
|
|
|
|
|
Disturbance In Attention |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Dizziness |
1/7 (14.29%) |
5/11 (45.45%) |
1/2 (50.00%) |
0/0 |
2/51 (3.92%) |
4/52 (7.69%) |
2/50 (4.00%) |
Dysgeusia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
4/52 (7.69%) |
1/50 (2.00%) |
Headache |
4/7 (57.14%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
10/51 (19.61%) |
13/52 (25.00%) |
4/50 (8.00%) |
Hyperaesthesia |
0/7 (0.00%) |
0/11 (0.00%) |
1/2 (50.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Hypoaesthesia |
1/7 (14.29%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
1/50 (2.00%) |
Paraesthesia |
1/7 (14.29%) |
1/11 (9.09%) |
1/2 (50.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
1/50 (2.00%) |
Peripheral Sensory Neuropathy |
2/7 (28.57%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
4/52 (7.69%) |
0/50 (0.00%) |
Sensory Disturbance |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Sinus Headache |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Tremor |
0/7 (0.00%) |
2/11 (18.18%) |
1/2 (50.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Lethargy |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
7/52 (13.46%) |
2/50 (4.00%) |
Psychiatric disorders |
|
|
|
|
|
|
|
Anxiety |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
3/52 (5.77%) |
1/50 (2.00%) |
Confusional State |
2/7 (28.57%) |
0/11 (0.00%) |
1/2 (50.00%) |
0/0 |
1/51 (1.96%) |
1/52 (1.92%) |
0/50 (0.00%) |
Depression |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
2/50 (4.00%) |
Insomnia |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
10/51 (19.61%) |
8/52 (15.38%) |
1/50 (2.00%) |
Renal and urinary disorders |
|
|
|
|
|
|
|
Haematuria |
0/7 (0.00%) |
1/11 (9.09%) |
1/2 (50.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
0/50 (0.00%) |
Nocturia |
0/7 (0.00%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
3/50 (6.00%) |
Proteinuria |
5/7 (71.43%) |
6/11 (54.55%) |
0/2 (0.00%) |
0/0 |
13/51 (25.49%) |
16/52 (30.77%) |
7/50 (14.00%) |
Renal Failure Acute |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Renal Failure Chronic |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Renal Mass |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Pollakiuria |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
4/50 (8.00%) |
Reproductive system and breast disorders |
|
|
|
|
|
|
|
Vaginal Haemorrhage |
0/7 (0.00%) |
0/11 (0.00%) |
1/2 (50.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
|
|
|
Cough |
6/7 (85.71%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
20/51 (39.22%) |
9/52 (17.31%) |
16/50 (32.00%) |
Dysphonia |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
10/51 (19.61%) |
19/52 (36.54%) |
2/50 (4.00%) |
Dyspnoea |
1/7 (14.29%) |
7/11 (63.64%) |
1/2 (50.00%) |
0/0 |
11/51 (21.57%) |
11/52 (21.15%) |
11/50 (22.00%) |
Dyspnoea Exertional |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
1/52 (1.92%) |
5/50 (10.00%) |
Epistaxis |
2/7 (28.57%) |
5/11 (45.45%) |
1/2 (50.00%) |
0/0 |
9/51 (17.65%) |
4/52 (7.69%) |
12/50 (24.00%) |
Haemoptysis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
3/52 (5.77%) |
2/50 (4.00%) |
Lung Infiltration |
0/7 (0.00%) |
1/11 (9.09%) |
1/2 (50.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Nasal Congestion |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
1/52 (1.92%) |
1/50 (2.00%) |
Oropharyngeal Pain |
1/7 (14.29%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
2/52 (3.85%) |
2/50 (4.00%) |
Pleural Effusion |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
3/50 (6.00%) |
Pneumonitis |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
4/50 (8.00%) |
Productive Cough |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
2/50 (4.00%) |
Rhinorrhoea |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
2/50 (4.00%) |
Sinus Congestion |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Sputum Discoloured |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Upper-Airway Cough Syndrome |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Wheezing |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
2/50 (4.00%) |
Paranasal sinus discomfort |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
/0 |
1/51 (1.96%) |
0/52 (0.00%) |
0/50 (0.00%) |
Skin and subcutaneous tissue disorders |
|
|
|
|
|
|
|
Dermatitis Acneiform |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
1/50 (2.00%) |
Dry Skin |
3/7 (42.86%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
5/51 (9.80%) |
3/52 (5.77%) |
3/50 (6.00%) |
Ecchymosis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Erythema |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
2/50 (4.00%) |
Erythema Multiforme |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Hyperhidrosis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
1/50 (2.00%) |
Hyperkeratosis |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
0/52 (0.00%) |
1/50 (2.00%) |
Night Sweats |
1/7 (14.29%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
2/52 (3.85%) |
2/50 (4.00%) |
Palmar-Plantar Erythrodysaesthesia Syndrome |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
4/51 (7.84%) |
8/52 (15.38%) |
2/50 (4.00%) |
Petechiae |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Pruritus |
2/7 (28.57%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
7/51 (13.73%) |
3/52 (5.77%) |
7/50 (14.00%) |
Rash |
3/7 (42.86%) |
5/11 (45.45%) |
1/2 (50.00%) |
0/0 |
9/51 (17.65%) |
8/52 (15.38%) |
11/50 (22.00%) |
Rash Erythematous |
0/7 (0.00%) |
2/11 (18.18%) |
0/2 (0.00%) |
0/0 |
2/51 (3.92%) |
3/52 (5.77%) |
4/50 (8.00%) |
Rash Macular |
1/7 (14.29%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
5/50 (10.00%) |
Skin Mass |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
1/52 (1.92%) |
0/50 (0.00%) |
Skin Ulcer |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
2/52 (3.85%) |
1/50 (2.00%) |
Onychoclasis |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
3/50 (6.00%) |
Acne |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
3/50 (6.00%) |
Vascular disorders |
|
|
|
|
|
|
|
Aortic Dilatation |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
0/52 (0.00%) |
0/50 (0.00%) |
Deep Vein Thrombosis |
0/7 (0.00%) |
1/11 (9.09%) |
0/2 (0.00%) |
0/0 |
0/51 (0.00%) |
3/52 (5.77%) |
0/50 (0.00%) |
Hypertension |
5/7 (71.43%) |
4/11 (36.36%) |
0/2 (0.00%) |
0/0 |
21/51 (41.18%) |
26/52 (50.00%) |
5/50 (10.00%) |
Hypotension |
1/7 (14.29%) |
3/11 (27.27%) |
0/2 (0.00%) |
0/0 |
3/51 (5.88%) |
1/52 (1.92%) |
0/50 (0.00%) |
Hot Flush |
0/7 (0.00%) |
0/11 (0.00%) |
0/2 (0.00%) |
0/0 |
1/51 (1.96%) |
3/52 (5.77%) |
0/50 (0.00%) |
Term from vocabulary, MedDRA 19.1
Indicates events were collected by non-systematic assessment
Indicates events were collected by systematic assessment
|